Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444443 | 0.86 | HTR2A (0.71) | CHRNB2CHRNA7CHRNA4HTR2CHTR2A | |
| SCHEMBL733712 | 0.86 | HTR2A (0.71) | CHRNB2CHRNA7CHRNA4HTR2CHTR2A | |
| SCHEMBL24144797 | 0.86 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4HTR2CHTR2A | |
| SCHEMBL2533934 | 0.83 | HTR2A (0.76) | CHRNB2CHRNA7CHRNA4HTR2CHTR2A | |
| SCHEMBL32684044 | 0.83 | HTR2A (0.76) | CHRNB2CHRNA7CHRNA4HTR2CHTR2A | |
| SCHEMBL27929613 | 0.82 | GPR84 (0.72) | CHRNB2CHRNA7CHRNA4HTR2ATRPM8 | |
| Hydrochloric Acid SCHEMBL2706928 | 0.81 | HTR2A (0.73) | CHRNB2CHRNA7CHRNA4HTR2CHTR2A | |
| SCHEMBL30517178 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA7CHRNA4NPC1HTR2C | |
| SCHEMBL21132337 | 0.81 | HTR2C (0.75) | NPC1HTR2CHTR2ACYP2D6SLC6A4 | |
| SCHEMBL20913762 | 0.80 | NPC1 (0.52) | CHRNB2CHRNA7CHRNA4NPC1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| CN-115772183-A | Indolylethyl fluoroboric acid derivatives, and preparation method and application thereof | 复旦大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-114957266-A | Total synthesis method of natural product aurantialcaine racemate | 上海应用技术大学 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2009006089-A2 | A2 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | disclosed |
| US-7217730-B2 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| US-5830911-A | ANTIARTHRITIC AGENTS; ANTICARCINOGENIC AGENTS; ALZHEIMER'SDISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| US-5824699-A | COMPOUNDS FOR TREATMENT OF ARTHRITIS, COLORECTAL CANCER AND ALZHEIMER'S DISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-10-20 | — | — | US | disclosed |
| US-5776967-A | ANTIINFLAMMATORY AGENTS; THERAPY FOR ARTHRITIC DISORDERS, COLORECTAL CANCER AND ALZHEIMER'S DISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | CHRNB2 2182/4885CHRNA7 2170/4885CHRNA4 2872/4885 |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | CHRNB2 4554/4885CHRNA7 3514/4885CHRNA4 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.